Kornimate/medical-research-clean huggingface dataset:
tdcs for laryngeal dystonia

Conditions: Laryngeal Dystonia

Summary: this project will apply transcranial direct current stimulation (tdcs) to multiple brain areas to evaluate the effects as a potential treatment for laryngeal dystonia (formerly spasmodic dysphonia).

baseline neuroimaging data will be acquired from all participants via mri, eeg. each participant will be seen for multiple testing sessions over a five day period. ld participants will undergo the neuromodulation (hd-tdcs stimulation) for twenty minutes while engaged in watching videos/movies or performing a word production task.

Eligibility criteria:
inclusion criteria: * participants must be clinically evaluated for the diagnosis of ld or have the proof of ld diagnosis. (not applicable for control participants) * no other known or history of speech, voice disorder other than ld. * provision of signed and dated informed consent form. * stated willingness to comply with all study procedures and availability for the duration of the study * must not be pregnant. exclusion criteria: * all individuals who do not meet the above mentioned criteria are excluded from the study. * subjects with a history of epilepsy or depression or is claustrophobic.
meld esas evolution: assessment of the symptomatic burden of patients with advanced chronic liver disease

Conditions: Palliative Care; End Stage Liver DIsease

Summary: the goal of this observational study is to understand if there is a correlation between the evolution of meld-na and symptomatic burden of patients with advanced chronic liver disease. all patients with chronic liver disease will be invited to participate in the study. patients will be followed prospectively with assessment of their meld-na score and symptom burden, according to the edmonton symptom assessment system scale.

1. methodology - prospective observational study 2. population - all patients with chronic liver disease followed in the matosinhos local health unit after their first episode of decompensation or are diagnosed with hepatocellular carcinoma in stage c or d of the barcelona liver clinic cancer will be invited to participate in the study. all patients who do not sign consent to participate, patients under 18 years of age and patients who present a recurrent degree of encephalopathy, according to the west-haven scale, equal or greater than 2, will be excluded. 3. sample - non-probabilistic for convenience 4. data collection instrument - patients will be followed prospectively with quarterly assessment, or after each episode of decompensation, of their meld-na score and symptom burden, according to the edmonton symptom assessment system scale (esas), with introduction of 3 other symptoms prevalent in patients with chronic liver disease: sexual dysfunction sexual, cramps and pruritus. the minimum analysis for each patient will be 2 assessments. all symptoms greater than 5 points will be considered moderate to severe and formal referral to the palliative care team will be discussed with the patient and their attending physician. subsequently evaluating its effectiveness in symptomatic control. 5. aims - this observational study will try to understand if there is a correlation between the evolution of meld-na and symptomatic burden of patients with advanced chronic liver disease. as well as the influence that the implementation of palliative care have on symptom burden of advanced chronic liver disease patients.

Eligibility criteria:
inclusion criteria: * all patients with chronic liver disease exclusion criteria: * do not sign consent to participate * patients under 18 years of age * patients who present a recurrent degree of encephalopathy, according to the west-haven scale, equal or greater than 2

Keywords: hepatology end stage liver disease palliative care
cilostazol versus aspirin for primary prevention of atherosclerotic events

Conditions: Type 2 Diabetes Mellitus

Summary: this multi-center, randomized controlled study aims to evaluate the efficacy of cilostazol versus aspirin for primary prevention of atherosclerotic events with korean type 2 diabetes mellitus (dm) patients.


Eligibility criteria:
inclusion criteria: 1. type 2 diabetes mellitus with high risk of macrovascular complications; high risk is one or more as follows: * hypertension (≧ 140/90 or anti-hypertensive therapy) * hypercholesterolemia (ldl-c \> 130 mg/dl or anti-hyperlipidemic therapy) * tg \> 200 mg/dl * non proliferative retinopathy or macular edema * microalbuminuria or macroalbuminuria * smoker 2. patients on no anti plt drug history 3. patients who are agree with this research exclusion criteria: 1. type 1 diabetes mellitus 2. macrovascular complication history 3. uncontrolled hypertension, unstable angina history 4. congestive heart failure 5. bleeding tendency 6. chronic liver disease (alt \> 100 or ast \> 100) or chronic renal disease creatinine \> 3.0 mg/dl) 7. anemia (hemoglobin \< 10 mg/dl) or thrombocytopenia (platelet count less than 100,000/mm3) 8. pregnant or lactation women 9. plan to be revascularized in 4 weeks 10. plan to go to surgery or invasive intervention in 4 weeks 11. plan to need to admission for acute cardiovascular disease in 4 weeks 12. contraindication of this medication 13. other anti-plt drug therapy

Keywords: cilostazol versus aspirin anti-plt drug primary prevention of atherosclerotic events type 2 dm intima media thickness (imt)
safety and efficacy of baf312 in dermatomyositis

Conditions: Active Dermatomyositis

Summary: this study investigated the dose response relationship for the efficacy and safety of baf312 compared to placebo in active dm patients over a treatment period of 6+6 months and to determine the minimum dose required for a maximal clinical effect. the study was composed of 2 periods: a double-blind period 1 with baf312 administered at different daily doses (0.5, 2, 10 mg and placebo) and a fixed-dose period 2 in which baf312 was administered at the dose of 2 mg daily .

the study was prematurely terminated based on the results of an interim analysis where baf312 did not demonstrate superior efficacy over placebo and a dose-response relationship was not observed. there were no safety concerns. approximately 56 participants were planned to be randomized. a total of 17 participants were enrolled and randomized by the time the study was terminated.

Eligibility criteria:
key inclusion criteria: written informed consent must be obtained before any assessment is performed. * patients who have been defined as "definite" or "probable" based on the criteria of bohan and peter (bohan and peter 1975) for dermatomyositis at least 3 months before screening * patients must have active disease as defined by muscle weakness * patients may be on a stable dose of corticosteroid (up/equal to 20 mg once daily prednisone equivalent) * patients currently treated with oral or subcutaneous mtx must have been a stable dose of no more/equal to than 25 mg per week * patients currently treated with azathioprine must have been a stable maintenance dose of no more/equal to 3 mg/kg/day * negative cancer screening conducted in the 12 months prior to screening visit key exclusion criteria * dermatomyositis patients having overlap myositis or any other type of myositis including paraneoplastic myositis, drug-induced myopathy, necrotizing myositis * preexisting severe cardiac or pulmonary conditions, malignancy of any organ system or significant eye diseases. * uncontrolled diabetes mellitus or diabetes complicated with organ involvement. * pregnant or nursing (lactating) women

Keywords: dermatomyositis
the effect of exposure to aversive non-verbal vocalizations on pain tolerance

Conditions: Healthy

Summary: humans produce non-verbal vocalizations (shouting, growling, screaming), laughter, ...) in various contexts that are likely to perform biological functions. and important social issues. yet despite their importance in the human vocal repertoire, the mechanisms and functions of non-verbal vocalizations remain little studied and poorly understood including in humans. in this context, the investigators wish to examine how the perception of vocalizations non-verbal aversive behaviours influence pain tolerance in healthy adults.

humans produce nonverbal vocalisations such as screams, grunts, roars, cries and laughter across a variety of contexts. yet despite the prominence and apparent importance of these nonverbal sounds in human communication, the investigators still know very little about their influence on human perception and behaviour. that's why, in this study, the investigators will examine specifically the influence of nonverbal vocal perception on pain tolerance. the remainder of the study will involve up to three trials of a pain tolerance (cold pressor) task, during which the investigators will ask participants to listen to vocalisations (e.g., babies' cries or babbling) while submerging the participant's hand in bath of circulating cold water. the results of the study will contribute to theoretical understanding of the functions of nonverbal vocal communication in humans, in particular the influence of nonverbal vocal and perception (of babies' cries) on pain tolerance.

Eligibility criteria:
inclusion criteria: * participant in good health * affiliated or entitled participant in a social security scheme * participant who received informed information about the study and co-signed, with the investigator, a consent to participate in the study exclusion criteria: * chronic pain * high blood pressure or poor circulation * cardiac or vascular disease, or a heart condition (including symptoms of raynaud's syndrome) * allergy or hypersensitivity to cold * diabetes * epilepsy * pregnancy * recent serious injury * neurological or psychiatric condition known to affect pain tolerance (e.g., peripheral neuropathy, schizophrenia) * history of fainting or seizures * history of frostbite

Keywords: nonverbal vocal communication babies cries pain tolerance cold pressor test
heartrate variability and intraoperative brain conditions in supratentorial tumors

Conditions: Supratentorial Brain Tumors

Summary: this study aims to determine the relationship between heart rate variability and intraoperative brain relaxation conditions in patients with brain tumors.

patients undergoing brain surgery for treatment of brain tumors will be studied to determine the relationship between heart rate variability and intraoperative brain relaxation conditions.

Eligibility criteria:
inclusion criteria: * patient aged 18 to 75 years * asa(american society of anesthesiologists ) i - iii * patients undergoing surgery for supratentorial tumors * glasgow coma scale \> 10 exclusion criteria: * patient aged below 18 and above 75 years. * pregnancy * asa(american society of anesthesiologists) iv-v * previous cranial surgery * morbid obesity ( bmi\>40) * ocular injury/ glaucoma * head injury * patient on beta blockers, ace(angiotensin-converting-enzyme) inhibitors, clonidine * diabetes mellitus for more than 5 years

Keywords: heart rate variability, supratentorial brain tumors optic nerve sheath diameter
postoperative antimicrobial prophylaxis versus placebo for infection prevention in hcc after liver resection

Conditions: Hepatocellular Carcinoma; Postoperative Infection

Summary: this trial is a multi-center, double-blinded, randomized (1:1) clinical trial. the aim is to compare the postoperative infection rate between the 3 days postoperative amp group and the placebo group in hcc patients undergoing hepatectomy.

this trial includes two phase. the first phase is the internal pilot study to explore the expulsion rate and recruited population. the second phase is the main phase iii trial.

Eligibility criteria:
inclusion criteria: * age: over 18 years; * diagnosed as primary hcc according to the easl criteria and plan to receive hepatectomy; * child-pugh a class; * no history of antibiotics in 1 week before surgery, except for antimicrobial prophylaxis in the 24h before surgery. * no evidence of infection during preoperational assessment exclusion criteria: * underwent hepatectomy combined with resection of other organs, except for gallbladder; * found obvious infection during operation; * combination with other operations, such as biliary reconstruction or tube drainage, bile duct exploration and stone remove, etc.; * allergic to the antibiotics used in the 24h before surgery; * emergency surgery; * tumor rupture; * did not underwent hepatectomy because of any reasons; * admission to icu after surgery; * asa grade ≥ 3; * denial of informed consent.
clinical evaluation of the combination of symptoms and symptoms with general treatment for acute hemorrhagic stroke

Conditions: Acute Hemorrhagic Stroke

Summary: objective to evaluate whether xingnaojing injection combined with naoxueshu oral liquid can significantly improve the clinical outcome of patients with intracerebral hemorrhage. secondary objectives included to evaluate whether combined application of xingnaojing injection and naoxueshu oral liquid can promote hematoma absorption or reduce perihematoma cerebral edema in patients with intracerebral hemorrhage

objective to evaluate whether xingnaojing injection combined with naoxueshu oral liquid can significantly improve the clinical outcome of patients with intracerebral hemorrhage. secondary objectives included to evaluate whether combined application of xingnaojing injection and naoxueshu oral liquid can promote hematoma absorption or reduce perihematoma cerebral edema in patients with intracerebral hemorrhage statistical methods: the main effective outcomes will be based on a generalized linear model and adjusted for associated confounders.

Eligibility criteria:
inclusion criteria: * ① it meets the diagnostic criteria of primary cerebral hemorrhage. * within 72 hours of onset. * national institutes of health stroke scale (nihss) score ≥4 points. ④ glasgow coma scale (gcs) score \&gt; eight points. ⑤ age 18-80. patient or legal representative informed consent, and sign informed consent. exclusion criteria: * (1) known to xingnaojing, cerebral hemorrhage or related drug ingredients allergic. * the patients with previous stroke history and remaining sequelae affected the outcome assessment, that is, the modified ranking scale (mrs) score before the onset of stroke was ≥2 points. (3) known by amyloid cerebrovascular disease, vascular malformation, aneurysm, blood coagulation dysfunction, anticoagulation and antiplatelet drug treatment, thrombolysis therapy, bleeding after infarction after conversion, haematology, moyamoya disease, primary or metastatic tumor, venous sinus thrombosis, and vascular inflammation caused by clear etiology of patients with cerebral hemorrhage or primary intraventricular hemorrhage. (note: "after anticoagulant or antiplatelet therapy" refers to patients with intracerebral hemorrhage following anticoagulant and antiplatelet therapy, and these patients were excluded from this study.) (4) patients with traumatic cerebral hemorrhage. (5) patients with active gastrointestinal ulcer or other definite tendency of rebleeding.
evaluation of raltegravir during the third trimester of pregnancy

Conditions: HIV-1 Infection; PREGNANCY

Summary: the purpose of this study is to assess the evolution of raltegravir concentration in the mother (between the 3rd trimester of pregnancy and one month post-delivery) and her neonate, when this drug is used to prevent mother-to-child hiv-1 transmission as part of a combined antiretroviral regimen.

1. objectives 1. principal objective * to study pharmacokinetic properties of raltegravir in pregnant women infected by hiv-1, during the third trimester of pregnancy (between 30 and 37 weeks of amenorrhea) and 1 month after childbirth (between w4 and w6 postpartum), as well as in their neonate. 2. secondary objectives * estimate the frequency of women receiving raltegravir and having indetectable viral load at delivery (and those having a strictly indetectable viral load, with no signal under the threshold of the technique used). * describe the tolerance to raltegravir in pregnant women during the third trimester and in her neonates 2. methodology * national multicenter pharmacokinetic study conducted among pregnant women infected by hiv-1 and exposed to raltegravir during pregnancy. 3. statistical method * method of population pharmacokinetic with 5 samples: before the drug intake, 0.5, 3, 8 and 12 hours after the intake at each of the 2 visits (between 30 and 37 weeks of amenorrhea, and 4 to 6 weeks after delivery).

Eligibility criteria:
inclusion criteria: * pregnant woman, between 30 and 37 weeks of amenorrhea * 18 years old and over * infected by hiv-1 * receiving a therapeutic combination, stable for at least 15 days before inclusion, with raltegravir at the standard dose (400 mg twice daily) which the doctor plans to maintain till the end of pregnancy and at least one month after delivery * informed consent signed by mother and investigator (at the latest day of pre-inclusion and before any examination conducted as part of research) * affiliated person or beneficiary of a social security system (medical aid of state or ame is not a social security system) * participant agreeing to be registered in the national file of the people who participate in biomedical researches exclusion criteria: * infected by hiv-2 * under 18 years old * receiving therapeutic association with atazanavir (reyataz®), fosamprenavir (telzir®), or efavirenz ( contained in sustiva® and atripla®) * currently using medication, drugs or alcohol which can interfere with the research: rifampicine, phénobarbital, phénytoïne, topical gastrointestinal, antiacid and adsorbents * presenting a clinical situation or acute pathology incompatible with the realisation of a pharmacokinetic study. * planned absence which could hinder research participation (travel abroad, moving, imminent transfer ...) * participating in another research, except the french perinatal survey (anrs co1 epf or anrs co11 observatory), including an exclusion period still in progress at the pre-inclusion * person under guardianship, or deprived of freedom by a judicial or administrative decision

Keywords: hiv-1 hiv mother to child prevention raltegravir pharmacokinetic
il17 rate and spondyloarthritis

Conditions: Spondylarthritis

Summary: there are, to date, no validated biomarkers or head-to-head rcts of biologics to guide choice of biologic agent in axspa. while there are now two head-to-head studies of a tnf inhibitor (tnfi) vs an il-17 inhibitor (il-17i) in psoriatic arthritis. recommendations refers to biological dmards (bdmards) including tnfi and il-17i for patients with high disease activity despite the use (or intolerance/contraindication) of at least two non-steroidal anti-inflammatory drugs (nsaids) in axial spa (axspa) and in failure of a strategy including methotrexate for psoriatic arthritis. a tool to help us to decide which bdmards to use is necessary. in spa, the method of determination of il17 seems to be questionable. the determination of cytokines after stimulation of immune cells in patients with active spa requiring a biological treatment could provide us with a tool to assist in the choice of therapy. the aim of the study was to show the feasibility of cytokine assay following lymphocyte stimulation in active spa requiring biological treatment. and secondly, to show the predictive character of this expression on the therapeutic response at three months after the implementation of a biological treatment.


Eligibility criteria:
inclusion criteria * patients with spondyloarthritis meeting the asas criteria * patients who were to benefit from the implementation of a biological treatment after failure of at least two nsaids. * patients having an active disease defined by a bath ankylosing spondylitis disease activity index (basdai) higher than four, exclusion criteria * no predominant axial manifestation, * having received a previous biological treatment * patients presenting contraindication to the implementation of these treatments.
drainage seton with flap versus eas preserving seton in treatment of transsphincteric anal fistula

Conditions: Anal Cancer

Summary: patients with high trans-sphincteric anal fistula will be randomized to one of two equal group: group 1 will have drainage seton with mucosal advancement flap and group 2 will undergo external anal sphincter sparing seton


Eligibility criteria:
inclusion criteria: * patients suffering from high trans-sphincteric anal fistula exclusion criteria: * acute sepsis. * specific cause of fistula e.g. crohn's disease * strictured anorectum. * any degree of incontinence * recurrent anal fistula. * low anal fistula. * previous anorectal surgery.
a cohort study on the efficacy of bariatric surgery for rapidly progressing diabetic nephropathy

Conditions: Bariatric Surgeries; Diabetic Nephropathy

Summary: establish a cohort of diabetic kidney disease(dkd) patients with intensive weight loss treatment to evaluate the impact of intensive weight loss treatment on the renal prognosis of dkd and construct a prediction model for the improvement of renal outcomes after weight loss.


Eligibility criteria:
inclusion criteria: * age 18 to 65 years old; * bmi\>25kg/m2 or abdominal obesity (i.e. waist circumference\>90cm for men and\>85cm for women); * egfr\<30ml/min/1.73m2 or urinary microalbumin≥300mg/g, egfr\<60ml/min/1.73m2. exclusion criteria: * patients who are taking glucocorticoids; * combined with tumors; ③combined with autoimmune diseases; ④serum albumin\<25g/l.
a study of maribavir in adults with post-transplant cytomegalovirus (cmv) infection in argentina

Conditions: Cytomegalovirus (CMV)

Summary: the main aim of this study is to learn about the safety of maribavir in adults with post-transplant cytomegalovirus (cmv) infection in routine clinical practice in argentina. the other aim is to study the effectiveness of the treatment with maribavir in routine clinical practice in argentina. participants will be treated by their doctors according to normal medical practice. study data will be collected either from information already available in the medical records or during study conduct.


Eligibility criteria:
inclusion criteria: * adult participants (18 years or older) with post-transplant cmv infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet in the real-world setting of common clinical practice in argentina. * have received at least one dose of maribavir according to approved indications. * have signed the mandatory informed consent that has been agreed with national regulatory authorities (anmat) as applicable. exclusion criteria - there are no specific exclusion criteria.
subfoveal choroidal thickness after surgery for age-related cataracts

Conditions: Cataract

Summary: to compare the effects of femtosecond laser-assisted cataract surgery (flacs) and conventional phacoemulsification surgery (cps) on subfoveal choroidal thickness (sfct) in age-related cataracts.

it is not clear whether femtosecond laser-assisted cataract surgery (flacs) alters retinal and choroidal thickness. the goal of the present study was to determine the changes of retinal and choroidal thicknesses in patients who have undergone flacs compared to patients who have undergone conventional phacoemulsification surgery (cps).

Eligibility criteria:
inclusion criteria: * the cataract stages of the patients were between n2 and n4 according to the locs iii. exclusion criteria: * eyes with histories of ocular surgery, trauma, and ocular diseases, including diabetic retinopathy, age-related macular degeneration (amd), high myopia, psudoexfoliation, uveitis, retinal vein occlusion, and other inflammatory and vascular retinal disorders.

Keywords: femtosecond laser-assisted cataract surgery (flacs) subfoveal choroidal thickness (sfct) conventional phacoemulsification surgery (cps)